EUROMYASTHENIA [ www.euromyasthenia.org ] - Le projet EuroMyasthenia

Informations

Le projet EuroMyasthenia

Vue d'ensemble : Titre [en]

Vue d'ensemble : Résumé [en]
Vue d'ensemble : Activités [en]

Partenaires associés

Partenaires collaborant au réseau

Lettre d'information

Comment utiliser ce site ?

To submit [en]

Activités ...

Travail de recherche dans le Réseau

Agenda

Préférences

259 membres

Utilisateurs en ligne

( personne )

Webmestre - Infos

Le projet EuroMyasthenia - Vue d'ensemble : Résumé [en]

Myasthenia Gravis (MG) is a rare and heterogeneous neuromuscular disease leading to abnormal fatigability of various muscles, with a prevalence of about 100 per million and an incidence which appears to be increasing.

The cause of MG could be genetic or aquired. The genetic forms incriminate several types of mutations in the acetylcholine receptor or associated proteins. Acquired MG has an autoimmune etiology; it is due to auto-antibodies to acetylcholine receptor found in 85% of patients, or other muscle endplate proteins such as MuSK.

MG could appear in young adults, essentially females, while the late onset form is distributed equally in males and females.

Treatment of autoimmune MG disease is symptomatic, with the use of cholinesterase inhibitors, and empiric, with the use of immunosuppressors, broad anti-immune therapy such as plasma exchange and intravenous immunoglobulins, and thymectomy for selected patients.

Clinical classification of MG differentiates between purely ocular and generalised forms, but also between late and early onset forms. To this date, it is not possible to know if these forms are different entities or whether they are a part of a continuum.

There are no differential diagnostic tests, the clinical features and evolution are very similar, and currently the same empiric therapies are used for all the groups.

A network concerning acquired MG was created several years ago and was supported by the AFM (French association against myopathies). This project gave the basis of a structured coordinated network on MG including several scientific investigators and clinicians.

Because this network has minimal budget, its activities were limited to exchanges between the experts in this field, and an annual meeting. However, the development of this network has established the necessary background for developing a sustainable coordination in the area of health information, collection of epidemio-logical data, exchange of data, and information within and between Member States.

The EuroMyasthenia project will cover essentially acquired MG, although hereditary MG patients could be integrated in a further step.

Back < > Next

Date de création : 24/10/2006 - 4:57 PM
Dernière modification : 18/05/2007 - 4:28 PM
Catégorie : Le projet EuroMyasthenia
Page lue 2069 fois

Prévisualiser la page Imprimer la page

Réactions à cet article

Personne n'a encore laissé de commentaire.
Soyez donc le premier !

Lettre d'information

Recherche

Zone d'accès restreint

Cette zone est dédiée aux cliniciens, chercheurs et associations de patients qui sont partenaires dans le réseau 'EuroMyasthenia' (associés et collaboratifs).

Entrez

(vous devez avoir un login et un mot de passe spécial)

Visites

visiteurs

visiteur en ligne